Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegenzileukin + Pembrolizumab in lung cancer and mesothelioma
NCT04914897Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Sep 2021
- Primary completion
- Jul 2023
- Modality
- Cytokines & Interferons
- Countries
- 11
01
Overview
Phase 2, open-label trial of pegenzileukin in non-small cell lung cancer (NSCLC) and pleural mesothelioma (4 cohorts), sponsored by Sanofi. Primary endpoint: Objective Response Rate at 14 months. Started Sep 2021; status: terminated.
02
Drugs
pegenzileukin
03
Conditions
non-small cell lung cancer (NSCLC)pleural mesothelioma
Beyond the preview
Go deeper on NCT04914897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04914897.